TGFB1 and neoplasm: Finally, it is also noteworthy that pasireotide-treatment decreased the phosphorylation levels of key factors involved in the TGF-β signalling-pathway (associated with aggressiveness in gliomas [88, 89]), such as JUN (responsible for tumour-invasion [89]).